Abstract
A many years of study and research, the noninvasive assessment of myocardial perfusion by echocontrast agents is becoming a clinical reality.1–9 The use of some firstand second-generation contrast agents (Levovist, Schering AG, Berlin, Germany; and Optison, Mallinckrodt Medical, Northampton, MA) on humans has been recently approved in Europe and the United States. The fast, technologic progress of echocardiographic imaging explains the growing interest in this new methodology. Before starting on this scientific journey, however, it is necessary to have the information with which to avoid all the pitfalls previously observed with other perfusion techniques. Several technical details relating to both imaging instrumentation and contrast agents require consideration to obtain an appropriate myocardial opacification by intravenous contrast media injection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
